Novartis has tapped up an artificial-intelligence-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for immuno-dermatology conditions. What caught the Swiss pharma’s eye is the so-called…
ORLANDO, Fla.—Novartis is divulging details from ianalumab’s summertime phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could delay the progression of patients to…
Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but, as the company’s CEO sees it—it’s never about the price tag. “We’re not really too…
Novartis is pulling back the curtain on late-stage Sjögren’s wins, revealing an edge for its investigational monoclonal antibody ianalumab over placebo in both studies. “Clearly, with Sjögren’s having no approved…
Almost a year after buying Kate Therapeutics, Novartis has scooped up another San Diego-based muscle dystrophy biotech in one of the biggest acquisitions of 2025 so far. The Swiss pharma…
Novartis has stuck on a second deal to its partnership with molecular glue degrader biotech Monte Rosa Therapeutics that includes a $120 million upfront payment. At the center of the…